Pulmonary Rehabilitation

📋 Key Information Summary

📋

Pulmonary rehabilitation (PR) is a structured, multidisciplinary program of exercise training, education, and self-management support for people with chronic respiratory disease — it is the single most effective non-pharmacological intervention for COPD.
Strongest indication is COPD with persistent dyspnea (mMRC ≥ 2) despite optimal pharmacotherapy; referral should not wait until end-stage disease.
Evidence also supports PR in interstitial lung disease (ILD), pulmonary hypertension (PAH/CTEPH), bronchiectasis, pre- and post-lung surgery, and post-COVID-19 persistent breathlessness.
The Australian Lung Foundation's Lungs in Action® and LungNet programs provide community-based maintenance pathways after hospital-based PR completion.
A standard PR program comprises 6–8 weeks (minimum 2 supervised sessions/week), ideally commencing within 2–4 weeks of referral to reduce dropout.
Exercise prescription includes endurance (walking or cycling) and peripheral muscle strength training; interval training is preferred for severely deconditioned patients.
Target intensity: 60–80% of peak work rate or 60–80% of 6-minute walk distance-derived speed; Borg dyspnoea score 3–5 / 10 as an intensity guide.
Minimum clinically important difference (MCID) for 6-minute walk test (6MWT) is 25–30 metres in COPD; for the Chronic Respiratory Questionnaire (CRQ), 0.5 units per domain.
PR significantly reduces hospital admissions and may reduce mortality in COPD; benefits wane after 12 months without a maintenance strategy.
Aboriginal and Torres Strait Islander peoples are under-referred to PR; culturally adapted programs with Indigenous health workers improve engagement and completion.
Contraindications include unstable angina, recent myocardial infarction (<4 weeks), uncontrolled heart failure, and musculoskeletal conditions preventing exercise — most comorbidities require modification, not exclusion.
PR is funded via Medicare (MBS items for chronic disease management plans) and state health services; private health funds typically cover hospital-based programs.

Introduction & Australian Epidemiology

Pulmonary rehabilitation (PR) is a comprehensive, evidence-based intervention comprising supervised exercise training, disease-specific education, nutritional counselling, and psychosocial support delivered by a multidisciplinary team. It is endorsed by the Thoracic Society of Australia and New Zealand (TSANZ), the Lung Foundation Australia, and international bodies (ATS/ERS) as a cornerstone of chronic respiratory disease management.

In Australia, chronic obstructive pulmonary disease (COPD) affects approximately 1 in 13 Australians aged ≥ 40 years and is the fifth leading cause of death. The Australian Institute of Health and Welfare (AIHW) reports over 7,600 COPD-related deaths annually. Interstitial lung disease (ILD), bronchiectasis, and pulmonary arterial hypertension (PAH) contribute additional substantial morbidity. The post-COVID-19 pandemic has further expanded the population living with chronic respiratory symptoms and functional limitation.

Despite strong evidence, PR utilisation in Australia remains alarmingly low. Fewer than 5% of eligible COPD patients are referred, and program completion rates average 50–60%. Barriers include limited program availability in rural and remote areas, long wait times, lack of clinician awareness, and patient transport difficulties. Lung Foundation Australia advocates for expanded access and has developed the Lungs in Action® community maintenance exercise program delivered across >150 sites nationally.

⚠️

Under-referral is a critical gap: Fewer than 1 in 20 eligible Australians with COPD access pulmonary rehabilitation. Clinicians should refer at first recognition of functional limitation (mMRC ≥ 2), not only after recurrent hospitalisations.

The economic burden is significant: COPD costs the Australian health system over $900 million annually in direct hospital costs, with exacerbations accounting for the majority. PR has been shown to reduce hospital readmissions by 30–40% in the 12 months following an exacerbation-related admission, making it one of the most cost-effective interventions in respiratory medicine.

Indications & Referral

Pulmonary rehabilitation is indicated for any patient with chronic respiratory disease who experiences persistent breathlessness, exercise limitation, or reduced health-related quality of life despite optimal medical therapy. Referral should be considered early in the disease course — not reserved for end-stage disease.

Primary Indications

Condition	Indication for Referral	Evidence Level
COPD	mMRC dyspnoea scale ≥ 2; FEV₁ < 80% predicted with symptoms; any recent exacerbation requiring hospitalisation or oral corticosteroids/antibiotics	Level I (Cochrane)
Interstitial Lung Disease (ILD)	IPF, hypersensitivity pneumonitis, connective tissue disease-ILD with exertional desaturation or functional limitation; stable disease on treatment	Level I (Cochrane)
Post-COVID-19	Persistent breathlessness and/or fatigue ≥ 4 weeks after acute illness; deconditioning; documented lung impairment or normal imaging with functional limitation	Level II
Pre/Post Lung Surgery	Pre-habilitation for lung cancer resection or transplant; post-surgical deconditioning; low predicted post-operative FEV₁ (<40% predicted)	Level II
Non-CF Bronchiectasis	Recurrent exacerbations, chronic breathlessness, sputum production, reduced exercise capacity	Level II
Pulmonary Arterial Hypertension	Stable PAH on targeted therapy; WHO functional class II–III; exercise limitation despite optimised pharmacotherapy	Level I (RCT)
Thoracic Malignancy	Pre-treatment deconditioning; breathlessness from lung cancer/mesothelioma; post-chemoradiation functional decline	Level III

Referral Criteria & Pathways

In Australia, referral pathways vary by state and territory. General practitioners can refer directly to hospital-based or community-based PR programs under a Chronic Disease Management (CDM) plan using MBS items 721 (GP Management Plan) and 723 (Team Care Arrangement). Patients may also self-refer to some community programs. Referral after an exacerbation-related hospital admission is a key quality indicator (Lung Foundation Australia's COPD-X guidelines recommend referral at discharge).

🚨

Post-exacerbation referral window: Commencing PR within 2–4 weeks of hospital discharge for a COPD exacerbation is associated with the greatest improvements in exercise capacity and the largest reduction in readmission risk. Delayed referral (>8 weeks) significantly reduces uptake and benefit.

Contraindications

Absolute contraindications are few. Most comorbidities require exercise modification rather than exclusion:

Absolute (rare)

Unstable angina or recent myocardial infarction (<4 weeks)
Acute decompensated heart failure
Severe aortic stenosis (symptomatic)
Acute pulmonary embolism
Acute febrile illness

Relative (modify, don't exclude)

Stable ischaemic heart disease
Controlled heart failure (NYHA I–III)
Musculoskeletal comorbidity (adapt exercises)
Peripheral vascular disease
Cognitive impairment (carer-assisted programs)
Supplemental oxygen requirement

Program Components

A comprehensive PR program comprises supervised exercise training, self-management education, nutritional counselling, and psychosocial support. Programs are delivered by a multidisciplinary team typically including a physiotherapist, respiratory physician, exercise physiologist, occupational therapist, dietitian, psychologist, social worker, and smoking cessation counsellor. The Lung Foundation Australia recommends a minimum of 6–8 weeks with at least 2 supervised sessions per week.

Multidisciplinary Team Roles

Discipline	Role in PR
Physiotherapist	Exercise prescription and supervision, 6MWT, breathing techniques (pursed-lip, diaphragmatic), airway clearance, mobility assessment
Exercise Physiologist	Cardiopulmonary exercise testing, exercise programming, strength assessment, community exercise transition
Respiratory Physician	Medical assessment, comorbidity management, oxygen titration, referral authorisation
Occupational Therapist	Energy conservation strategies, activities of daily living assessment, assistive equipment prescription
Dietitian	Nutritional assessment, weight management (obesity and cachexia), micronutrient advice, meal planning
Psychologist	Screening for anxiety/depression (PHQ-9, GAD-7), cognitive-behavioural therapy, motivational interviewing
Smoking Cessation Counsellor	Quit support, pharmacotherapy initiation (varenicline, NRT), relapse prevention
Indigenous Health Worker	Cultural liaison, yarning-based education, community engagement, transport coordination for ATSI patients

Exercise Training

Exercise training is the cornerstone of PR and the component with the strongest evidence base. It includes endurance (aerobic) training, peripheral muscle strength training, and flexibility/balance exercises. Exercise sessions should include warm-up (5–10 minutes), active training (20–40 minutes), and cool-down (5–10 minutes). All sessions should be supervised by a trained clinician with access to emergency resuscitation equipment, supplemental oxygen, and bronchodilators.

Education Sessions

Structured education should cover disease understanding, medication use (inhaler technique, oxygen therapy), action plans for exacerbation management, breathing strategies, energy conservation, nutrition, travel and altitude advice, advance care planning, and psychological well-being. Education should be interactive and culturally appropriate.

Nutritional Counselling

Both obesity (BMI ≥ 30) and low body weight (BMI < 18.5) are independent predictors of worse outcomes in COPD. Dietitian-led assessment should include body composition (ideally bioelectrical impedance), micronutrient status (vitamin D, iron), and sarcopenia screening. Protein intake of 1.0–1.5 g/kg/day is recommended to support exercise-induced muscle adaptation, particularly in cachectic patients.

Psychosocial Support

Anxiety and depression are prevalent in 40–60% of people with COPD and are associated with worse adherence, more frequent exacerbations, and increased mortality. Routine screening with the Hospital Anxiety and Depression Scale (HADS) or PHQ-9/GAD-7 should occur at PR entry. Cognitive-behavioural therapy (CBT), motivational interviewing, and peer support groups are effective adjuncts.

Outcome Measures

Domain	Tool	MCID	Timing
Exercise capacity	6-Minute Walk Test (6MWT)	25–30 m	Baseline and completion
Exercise capacity	Sit-to-Stand Test (1-min STS)	3 repetitions	Baseline and completion
Health-related QoL	Chronic Respiratory Questionnaire (CRQ-SR)	0.5 units/domain	Baseline and completion
Health-related QoL	COPD Assessment Test (CAT)	2 units	Baseline and completion
Dyspnoea	Modified Medical Research Council (mMRC) Dyspnoea Scale	1 grade	Baseline and completion
Dyspnoea	Borg Dyspnoea Scale (0–10)	1 unit	During exercise
Psychological	HADS / PHQ-9 / GAD-7	Variable	Baseline and completion
Physical activity	Activity monitor (accelerometer)	Context-specific	Baseline and 12-month

Exercise Prescription

Exercise prescription in pulmonary rehabilitation must be individualised based on baseline assessment, comorbidities, patient goals, and available resources. The three main modalities are endurance (aerobic) training, resistance (strength) training, and interval training. Peripheral muscle dysfunction is a key therapeutic target, as limb muscle weakness contributes more to exercise limitation than ventilatory impairment in many patients with COPD.

Endurance (Aerobic) Training

Endurance training is the most evidence-based component and may use walking (ground-based or treadmill) or cycling (stationary cycle ergometer). Cycling is preferred in severe COPD as it reduces the oxygen cost of locomotion and allows better symptom monitoring.

Parameter	Recommendation	Intensity Guide
Mode	Walking or cycling	—
Frequency	2–5 sessions/week (minimum 2 supervised)	—
Duration	20–30 minutes continuous (or accumulate in intervals)	Increase by 5 min/week
Intensity — % peak work rate	60–80% of peak work rate (from CPET)	Severe dyspnoea: start 40–50%
Intensity — % 6MWT speed	60–80% of average 6MWT speed	Calculate from 6MWT distance
Intensity — Borg dyspnoea	Target Borg 3–5 / 10 (moderate to severe)	Stop if Borg ≥ 7
Intensity — Borg fatigue	Target Borg 3–4 / 10	Stop if Borg ≥ 7

Resistance (Strength) Training

Peripheral muscle strength training targets quadriceps, hip flexors, and upper limb muscles. It produces additional gains in muscle strength and functional performance beyond endurance training alone and is recommended as a mandatory component of all PR programs (TSANZ/Lung Foundation Australia).

Parameter	Recommendation
Exercises	Quadriceps (leg press/squats), hamstrings, hip flexors, deltoids, biceps, triceps; minimum 4–6 exercises
Sets × Repetitions	1–3 sets of 8–12 repetitions
Intensity	60–70% of 1-repetition maximum (1-RM); begin 30–40% if severely deconditioned
Frequency	2–3 sessions/week (non-consecutive days)
Progression	Increase load by 5–10% when patient can complete 12 reps at current weight comfortably
Equipment	Free weights, resistance bands, ankle weights, weight machines; bands suitable for home/community programs

Interval Training

Interval training alternates short bouts of high-intensity exercise (30 seconds to 2 minutes at 80–100% peak work rate) with recovery periods (equal or longer duration at low intensity). It is particularly beneficial for patients who cannot sustain continuous endurance training due to severe ventilatory limitation, dynamic hyperinflation, or extreme deconditioning.

✅

Interval vs. continuous training: In severe COPD (FEV₁ < 40% predicted), interval training achieves comparable physiological benefits to continuous training with less dyspnoea and reduced risk of oxygen desaturation. It is the preferred starting modality for highly symptomatic patients.

1

Assessment

Baseline 6MWT, sit-to-stand, strength testing, SpO₂ monitoring, Borg scales, comorbidity review

2

Initial Prescription

Low-moderate intensity (40–60% peak work rate); short duration (10–15 min); interval if severely limited

3

Progressive Overload

Increase duration before intensity; add 5 min/week or 5–10% intensity every 1–2 weeks

4

Maintenance Transition

Referral to Lungs in Action®, community gym, or home exercise program with regular reassessment

Supplemental Oxygen During Exercise

Patients who desaturate to SpO₂ < 88% during exercise should receive supplemental oxygen titrated to maintain SpO₂ ≥ 88–90%. Ambulatory oxygen (portable concentrator or cylinder) enables higher training intensities and longer exercise durations. Exercise prescription should always include continuous pulse oximetry monitoring.

Breathing Strategies

Pursed-lip breathing during exercise reduces dynamic hyperinflation and improves ventilatory efficiency. Diaphragmatic breathing, active cycle of breathing technique (ACBT), and inspiratory muscle training (IMT, threshold loading at 30–40% maximal inspiratory pressure) are adjunctive techniques that may benefit selected patients, particularly those with bronchiectasis or severe dyspnoea.

Outcomes & Maintenance

The evidence base for pulmonary rehabilitation is among the strongest in respiratory medicine. Benefits span exercise capacity, dyspnoea, health-related quality of life, psychological well-being, healthcare utilisation, and survival. However, these benefits attenuate after 12–18 months without ongoing exercise maintenance, underscoring the critical importance of long-term adherence strategies.

Key Outcomes

Exercise Capacity

6MWT Improvement

Mean improvement of 44 m (COPD Cochrane review); well above the MCID of 25–30 m. Effect seen across GOLD stages.

Level I Evidence

Quality of Life

CRQ & CAT Scores

CRQ dyspnoea domain improves by 0.7–1.0 units (MCID 0.5). CAT score reductions of 2–3 points. SGRQ improvement 4–8 points (MCID 4).

Level I Evidence

Healthcare Utilisation

Hospital Admissions

30–40% reduction in COPD-related hospital readmissions at 12 months. Number needed to treat (NNT) of 4 to prevent one readmission.

Level I Evidence

📊

6MWT protocol standardisation: The 6MWT should be performed according to ATS/ERS 2002 guidelines: 30 m flat corridor, standardised encouragement phrases every minute, continuous pulse oximetry, and pre/post Borg dyspnoea and fatigue scores. Two practice tests are recommended at baseline to account for a learning effect.

Exacerbation Reduction

PR commencing within 4 weeks of an acute exacerbation significantly reduces the risk of subsequent exacerbations and hospital readmissions. A meta-analysis demonstrated a 40% relative risk reduction in hospital readmission at 12 months. PR also improves the speed of recovery from exacerbations and reduces the time to return to baseline functional status. Patients should be educated on self-management action plans with early rescue medication use (short-acting bronchodilators and corticosteroid packs).

Maintenance Strategies

The benefits of a standard 6–8 week PR program decline significantly by 12 months unless a maintenance strategy is in place. The following approaches should be discussed at program completion:

Weeks 1–8

Supervised hospital/centre-based PR program (2–3 sessions/week)

Weeks 8–12

Transition phase: supervised tapering (1 session/week) plus home exercise program initiation

Months 3–12

Community maintenance: Lungs in Action® (Lung Foundation Australia), community gym, or structured home program with monthly telephone support

Beyond 12 months

Ongoing self-managed exercise with periodic reassessment (6MWT, CAT) every 6–12 months; re-referral if decline noted

Long-Term Adherence Strategies

Strategy	Evidence & Practical Application
Home exercise programs	Written and video-based programs with pedometer/step-count targets; comparable outcomes to supervised programs in motivated patients (Level II)
Telephone/telehealth follow-up	Monthly coaching calls or video sessions improve exercise adherence and reduce hospital presentations (Level II). Particularly valuable in rural/remote Australia.
Lungs in Action®	Lung Foundation Australia's community maintenance program at >150 sites nationally; led by trained exercise professionals; low-cost group sessions
Activity monitoring	Pedometers and accelerometers with step-count goals (aim for 5,000–7,000 steps/day); digital health platforms for self-monitoring
Behavioural change techniques	Motivational interviewing, goal-setting, action planning, self-monitoring, social support, and relapse prevention planning
Re-referral	Patients who experience an exacerbation, significant functional decline, or haven't attended PR >12 months should be re-referred. Repeat PR is as effective as initial PR.

⚠️

Benefits wane without maintenance: Without an ongoing exercise strategy, gains in exercise capacity and quality of life return to baseline by 12–18 months. All patients completing PR must have a personalised maintenance plan documented before discharge.

Special Populations

Pulmonary rehabilitation must be adapted for special populations. Most patients with comorbidities can safely participate with appropriate modifications. Exclusion of older adults, those with multimorbidity, or patients with cognitive impairment leads to inequitable access.

👶

Paediatric

Indications CF-related lung disease, severe asthma, post-BPD, neuromuscular respiratory weakness; exercise programs adapted from adult PR models

Modifications Game-based and play-integrated exercise; age-appropriate education; family involvement mandatory; use of shuttle walk tests adapted for age

Key consideration Paediatric PR programs are scarce in Australia; CF-specific programs (e.g., at Royal Children's Hospital Melbourne, Children's Hospital Westmead) are the primary access point

👴

Elderly (≥ 75 years)

Considerations Multimorbidity (osteoarthritis, cardiac disease, diabetes) requires individualised programming; fall risk assessment; frailty screening (Clinical Frailty Scale)

Modifications Lower starting intensity (40–60% peak work rate); seated exercises if balance impaired; chair-based strength training; balance exercises added

Key consideration Older adults derive equivalent relative benefit from PR; chronological age alone should never be an exclusion criterion

🫘

Renal Impairment

Considerations CKD and dialysis patients have significant deconditioning and overlap with respiratory disease; electrolyte monitoring during exercise

Modifications Exercise on non-dialysis days; avoid exercise immediately post-dialysis (hypotension risk); monitor potassium if on RAAS inhibitors

🫁

Hepatic Impairment

Considerations Advanced liver disease (Child-Pugh B/C) with hepatopulmonary syndrome or portopulmonary hypertension requires specialist co-management

Modifications Monitor for coagulopathy (INR); avoid contact resistance exercises if portal hypertension with varices; ensure adequate nutrition

🛡️

Immunocompromised

Considerations Post-transplant (lung, bone marrow, solid organ), biologic therapy, chronic corticosteroids; infection risk during supervised sessions

Modifications Mask use during community programs if neutropenic; home-based PR may be preferred during high immunosuppression periods; post-lung transplant PR is strongly indicated and improves graft function

🤰

Pregnancy

Considerations Pre-existing respiratory disease (asthma, CF, ILD) may worsen in pregnancy; exercise is safe and encouraged with modifications

Modifications Avoid supine exercises after 16 weeks; intensity guided by the "talk test" (able to hold conversation); monitor for supine hypotension; avoid Valsalva manoeuvre during resistance training

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Chronic respiratory disease is a leading cause of the health gap between Aboriginal and Torres Strait Islander peoples and non-Indigenous Australians. COPD hospitalisation rates are 2.4 times higher in Indigenous Australians, and chronic lower respiratory disease is the sixth leading cause of Indigenous mortality. Despite this disproportionate burden, access to pulmonary rehabilitation for Indigenous Australians remains critically limited, particularly in remote and very remote communities.

🚨

Critical health gap: Aboriginal and Torres Strait Islander peoples experience COPD at rates 2.5 times higher than non-Indigenous Australians and develop disease 10–20 years earlier. Culturally safe PR programs are urgently needed to close this gap.

Access & Geography

Most PR programs are located in metropolitan and major regional centres. Remote and very remote communities — where COPD prevalence is highest — have almost no access. Telehealth-enabled and community-led programs are essential.

Cultural Safety

Mainstream PR programs may not be culturally appropriate. Integration of Indigenous health workers, yarning-based education, group exercise in community settings, acknowledgment of Country, and family-inclusive approaches improve engagement. Programs should be co-designed with local communities.

Workforce

Training Aboriginal Health Workers/Practitioners (AHW/AHP) in exercise prescription and respiratory education extends PR access. The Lung Foundation Australia and RHDAustralia provide culturally adapted training resources. Locally employed AHWs provide essential cultural brokerage.

Smoking & Early Onset

Smoking rates in Indigenous Australians are ~2.5 times the national average (~40% vs 16%). Quit support must be integrated into PR with culturally appropriate messaging. Respiratory disease onset is earlier; PR referral should begin by age 40 in symptomatic individuals.

Otitis Media & Hearing

High rates of chronic otitis media and hearing impairment require visual/written education materials and hearing loop availability. Education delivery must avoid reliance on verbal-only communication.

Housing & Environmental

Overcrowding, poor ventilation, and indoor smoke exposure (particularly in remote NT and WA communities) drive respiratory disease. PR should incorporate health promotion around housing and environmental health, in partnership with environmental health practitioners.

Transport & Logistics

Patient transport to PR sites is a major barrier. Funded patient transport services (through Aboriginal Community Controlled Health Organisations — ACCHOs), mobile PR services, and home-based exercise programs with remote monitoring can address this.

Maintenance & Community

Community-controlled exercise groups, walking groups on Country, and integration with existing Men's and Women's health programs provide sustainable maintenance pathways. The Lungs in Action® model can be adapted for Indigenous community settings with appropriate training.

Quick Reference: PR Prescription Summary

Endurance Training

Walking or cycling

20–30 min, 2–5×/week

60–80% peak WR; Borg 3–5

Resistance Training

4–6 exercises; upper & lower limb

1–3 sets × 8–12 reps, 2–3×/week

60–70% 1-RM; progress 5–10%/fortnight

Interval Training

30s–2 min high intensity

Equal or longer recovery bouts

80–100% peak WR; preferred if severe COPD

Education

Disease, meds, action plans, breathing

1–2 sessions/week

Interactive; culturally appropriate

Assessment

6MWT, CAT/CRQ, mMRC, STS

Baseline + completion (minimum)

6MWT MCID = 25–30 m

Maintenance

Lungs in Action® / home program

Ongoing post-completion

Reassess every 6–12 months

📚 References

1. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13–e64.
2. McCarthy B, Casey D, Devane D, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;(2):CD003793.
3. Alison JA, McKeough ZJ, Johnston K, et al. Australian and New Zealand Pulmonary Rehabilitation Guidelines. Respirology. 2017;22(4):800–819.
4. Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2014;(10):CD006322.
5. Morris NR, Kermeen FD, Holland AE. Exercise-based rehabilitation programmes for pulmonary hypertension. Cochrane Database Syst Rev. 2017;(8):CD011285.
6. Puhan MA, Gimeno-Santos E, Scharplatz M, et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;(10):CD005305.
7. Australian Institute of Health and Welfare. Chronic obstructive pulmonary disease (COPD). AIHW; 2023. Available from: https://www.aihw.gov.au/reports/chronic-respiratory-conditions/copd
8. Lung Foundation Australia. Pulmonary Rehabilitation Toolkit. 2023. Available from: https://lungfoundation.com.au/patients-carers/pulmonary-rehabilitation/
9. Singh SJ, Puhan MA, Andrianopoulos V, et al. An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1447–1478.
10. Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1428–1446.
11. Cox NS, Dal Corso S, Hansen H, et al. Telerehabilitation for chronic respiratory disease. Cochrane Database Syst Rev. 2021;(1):CD013040.
12. McNamara RJ, McKeough ZJ, McKenzie DK, Alison JA. Water-based exercise training for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;(12):CD008290.
13. Yang IA, Brown JL, George J, et al. COPD-X Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2024 update. Respirology. 2024;29(5):359–382.
14. World Health Organization. WHO consolidated guidelines on tuberculosis: module 4 treatment – drug-resistant tuberculosis treatment, 2022 update. Geneva: WHO; 2022.
15. Australian Government Department of Health and Aged Care. Medicare Benefits Schedule Book — Category 1: Professional Attendances. Canberra: Commonwealth of Australia; 2024.